Table 2.
Model Estimated Means for Treatment Outcomes Over Course of Study.
| Baseline | Post-Treatment | Follow-up | |
|---|---|---|---|
|
|
|||
| 7-day PPA | |||
| VARCC+PE | 0.0% | 20.0% | 9.8% |
| VARCC | 0.0% | 6.0% | 1.8% |
|
| |||
| PSS-I | |||
| VARCC+PE | 27.5 | 11.5 | 10.8 |
| VARCC | 28.9 | 19.3 | 16.8 |
|
| |||
| HAM-D | |||
| VARCC+PE | 15.5 | 6.8 | 7.3 |
| VARCC | 16.1 | 12.3 | 11.8 |
Note: VARCC, Varenicline and smoking cessation counseling; PE, Prolonged Exposure; PSS-I, PTSD Symptom Severity Inventory; HAM-D, Hamilton Depression Scale; 7-day PPA = point prevalence abstinence in the past 7 days. *= significant difference between groups at p<.01. The treatment groups had the following sample sizes: VARCC+PE = 72, VARCC = 70. Post-treatment is 3-months post-quit day. Follow-up is 6-months post-quit day.